Information Provided By:
Fly News Breaks for October 5, 2015
BLUE
Oct 5, 2015 | 06:28 EDT
Morgan Stanley analyst Matthew Harrison upgraded bluebird to Overweight with a $143 price target. Harrison said valuation now heavily reflects any potential competition in sickle cell disease and expects data at ASH in early December to be a key near-term catalyst. The analyst expects the data to show significant increases in hemoglobin similar to the first sickle cell disease patient.
News For BLUE From the Last 2 Days
There are no results for your query BLUE